21st Austria weekly - Valneva Vienna Stock Exchange 30/12/2022 [pic1]Valneva: an Austrian/French specialty vaccine company reported further heterologous booster data from exploratory small clinical study for its inactivated COVID-19 vaccine VLA2001. The show that a dose of VLA2001 was well tolerated in previously BNT162b2 Pfizer/BioNTech- or mRNA 1273 Moderna-vaccinated participants confirming the favorable safety profile seen across all studies – including homologous settings. However this study additional elicited only marginally increased neutralizing antibody response. Company positive results following primary vaccination with ChAdOx1-S AstraZeneca August